292 related articles for article (PubMed ID: 19070762)
1. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
J Oral Maxillofac Surg; 2009 Jan; 67(1):159-61. PubMed ID: 19070762
[TBL] [Abstract][Full Text] [Related]
2. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
[TBL] [Abstract][Full Text] [Related]
3. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study.
Demircan S; Isler SC
Niger J Clin Pract; 2020 Feb; 23(2):154-158. PubMed ID: 32031088
[TBL] [Abstract][Full Text] [Related]
4. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
5. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
7. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Hoefert S; Schmitz I; Tannapfel A; Eufinger H
Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
9. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
10. Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday.
Kwon YD; Kim YR; Choi BJ; Lee DW; Kim DY
Quintessence Int; 2009 Apr; 40(4):277-8. PubMed ID: 19417871
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Migliorati CA; Schubert MM; Peterson DE; Seneda LM
Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
[TBL] [Abstract][Full Text] [Related]
12. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
13. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Bagan JV; Jiménez Y; Gómez D; Sirera R; Poveda R; Scully C
Oral Oncol; 2008 Nov; 44(11):1088-9. PubMed ID: 18396443
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
15. Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.
Thumbigere-Math V; Michalowicz BS; Hughes PJ; Basi DL; Tsai ML; Swenson KK; Rockwell L; Gopalakrishnan R
J Oral Maxillofac Surg; 2016 Apr; 74(4):738-46. PubMed ID: 26501428
[TBL] [Abstract][Full Text] [Related]
16. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
Balla B; Vaszilko M; Kósa JP; Podani J; Takács I; Tóbiás B; Nagy Z; Lazáry A; Lakatos P
Oral Dis; 2012 Sep; 18(6):580-5. PubMed ID: 22339777
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
Kwon YD; Ohe JY; Kim DY; Chung DJ; Park YD
Clin Oral Implants Res; 2011 Jan; 22(1):100-5. PubMed ID: 20946206
[TBL] [Abstract][Full Text] [Related]
20. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
Udvardy E; Redl P; Márton I
Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
